2.Company name: Microbio Co., LTD.

3.Relationship to the Company (please enter ”head office” or

”subsidiaries”): head office

4.Reciprocal shareholding ratios: NA

5.Cause of occurrence:

Microbio Co., Ltd. was informed by the consulting firm today that Symbiota,the gut microbiome based

products exclusively developed by Microbio, achieves an Independent / Self-affirmed GRAS

（Generally Recognized as Safe）conclusion according to the U.S. FDA regulations.

6.Countermeasures:None

7.Any other matters that need to be specified(the information

disclosure also meets the requirements of Article 7, subparagraph 9

of the Securities and Exchange Act Enforcement Rules, which brings

forth a significant impact on shareholders rights or the price of

the securities on public companies.):

(1) Symbiota are the gut microbiome based products successfully developed by Microbio’s proprietary

symbiotic anaerobic fermentation technology using multi-strain probiotics, which are the cutting-edge

“postbiotics” comprises the metabolites from symbiotic fermentation of gut probiotics. MS-20, the first

approved new drug as an oral adjuvant therapy for chemotherapy in Taiwan, PrimeEnzyme available

in Cotton-Field Organic, Microsoy, Young, TB90010 that is a newly-developed microbiome based

product for type2 diabetes management, and LT17 for alleviating liver function are all developed by

Symbiota technology with different bacteria strains.

(2) According to the GRAS determination, Symbiota can be used in nutritional beverages, protein and

nutritional powder, smoothies, and grain drinks, regular and diet sports and energy drinks, regular

and diet soft drinks, fruit drinks including unreconstituted powders, dairy drinks, and milk substitutes,

gelatin-type candies, ready to eat cereals, and cooked cereals at usage levels up to 20% for the liquid

form and 10% for the powdered form. The intake analysis was for all ages (1-110 years).

(3) Multiple patents protection cover Symbiota product, technology, and use have been granted by major

countries in the world. Symbiota according to the regulations of different countries will adopt a diverse

regulatory strategies, including new drug, medical device, medical food, dietary supplement, and regular

food to accelerate the global market entry.

(4) The achievement of U.S. Independent / Self-affirmed GRAS conclusion for Symbiota is a key market

entry strategy of the company. Unlike probiotics, this GRAS conclusion is the first on the postbiotics

derived from symbiotic fermentation of multi-strain probiotics in Taiwan, and the GRAS conclusion

includes the soybean fermentates generated by multi-strain probiotics and yeasts or mixtures of these

strains, which covers all current Microbio’s proprietary microbiome-based portfolio.

(5) The clinical trial of MS-20 in combination with Pembrolizumab (anti-PD1 therapy) for the treatment of

metastatic non-small cell lung cancer (NSCLC) is currently ongoing. Obtaining the GRAS conclusion

will facilitate the product launch to global markets following the completion of the trial.